An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Trial Profile

An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Liprotamase (Primary)
  • Indications Exocrine pancreatic insufficiency
  • Focus Adverse reactions
  • Acronyms EASY
  • Sponsors Anthera Pharmaceuticals
  • Most Recent Events

    • 02 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2019.
    • 02 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2018.
    • 27 Feb 2017 According to an Anthera Pharmaceuticals media release, this study will also be offered to subjects completing the RESULT (profile 280130) and SIMPLICITY (profile 259576) studies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top